MARKET

VBLT

VBLT

VASCULAR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.160
-0.190
-14.07%
Closed 16:00 04/01 EDT
OPEN
1.260
PREV CLOSE
1.350
HIGH
1.330
LOW
1.100
VOLUME
221.35K
TURNOVER
--
52 WEEK HIGH
1.710
52 WEEK LOW
0.9000
MARKET CAP
41.93M
P/E (TTM)
-2.1390
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VBLT stock price target is 3.400 with a high estimate of 5.00 and a low estimate of 2.000.

EPS

VBLT News

More
  • Vascular Biogenics: A Buy On Promising Cancer Therapy
  • Seeking Alpha - Article · 17h ago
  • TherapeuticsMD Suspends Guidance, And Other News: The Good, Bad And Ugly Of Biopharma
  • Seeking Alpha - Article · 5d ago
  • Edited Transcript of VBLT earnings conference call or presentation 19-Mar-20 12:30pm GMT
  • Thomson Reuters StreetEvents · 6d ago
  • VBL Therapeutics Announces Positive Outcome of the Interim Analysis in the OVAL Phase 3 Ovarian Cancer Pivotal Study
  • GlobeNewswire · 6d ago

Industry

Biotechnology & Medical Research
-4.52%
Pharmaceuticals & Medical Research
-2.91%

Hot Stocks

Symbol
Price
%Change

About VBLT

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company's program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. Its lead product candidate, VB-111(ofranergene obadenovec), is a gene-based biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, is a Phase II-ready molecule.
More

Webull offers kinds of Vascular Biogenics Ltd stock information, including NASDAQ:VBLT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VBLT stock news, and many more online research tools to help you make informed decisions.